Insomnia Clinical Trial
— SOMNOTHERMOfficial title:
Evaluation of Psychosomatic Spa Treatment With Crenotherapy to Potentiate the Implementation of Behavioral Measures for Insomnia Disorder Management
Persistant insomnia is a common sleep disorder that affects approximately 20% of the French population. The standard treatment for chronic insomnia is Cognitive-Behavioral Therapy (CBT). Behavioral measures can be difficult to implement for the patient alone at home. Spa therapy with psychosomatic orientation allows to implement hygiene rules and structure rhythms of life. In addition, recent studies have shown that spa treatment, including crenotherapy, is effective in somatic complaints related to anxiety and benzodiazepine withdrawal. The spa treatment could therefore provide ideal conditions for the implementation of behavioral measures for insomnia management. The objective of SOMNOTHERM study is to measure efficiency on insomnia complaints at 8 weeks of a the implementation of a Behavioral therapy program for insomnia delivered by an internet software combined to a spa treatment compared to implementation of the same program at home (standard care).
Status | Recruiting |
Enrollment | 178 |
Est. completion date | December 2023 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Male or female aged between 18 and 80 years old - Registered at one of the participating spas, for a psychosomatic spa treatment scheduled for the next 12 months, but within a period of more than 16 weeks. - ISI score = 8 on the pre-selection questionnaire - Person with a persistent insomnia disorder, with or without comorbidities, according to DSM 5 - Owning or having access to a computer / tablet or smartphone and to an internet connection - Affiliated to a national health service - Having given written informed consent to participate in the trial. Exclusion Criteria: - Strong suspicion of obstructive sleep apnea (OSA) syndrome on the STOP-BANG questionnaire and restless legs syndrome on the RLS screening questionnaire - Having started antidepressant treatment in the last 2 months or whose treatment dose has been increased in the last 2 months - Having started treatment with anxiolytic, hypnotic or neuroleptic in the last month or whose dosage of treatment has been increased in the last month - Having carried out a spa treatment in the last 6 months, whatever the specialty. - Registered to follow a complementary program for insomnia disorders during the planned spa treatment - Pregnant or lactating women - Major under guardianship or curatorship - Night and shift-workers - Having undertaken trans-meridian travel (± 3H) in the previous 1 month |
Country | Name | City | State |
---|---|---|---|
France | University Hospital, Bordeaux | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
Association Francaise pour la Recherche Thermale | University Hospital, Bordeaux, University of Bordeaux |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Insomnia Severity Scale (ISI) score | 7-item questionnaire assessing insomnia nature, severity and impact. The global score ranges from 0 to 28. | Week 10 = 8 weeks after beginning of computerized behavioral therapy (starting of time in bed restriction) | |
Secondary | Total sleep time (TST) obtained by sleep diary | Total sleep time = total sleep episode minus awake time. Subject records in his online sleep diary bedtime, wake-up time, time asleep, intra-night awakenings. | Every night between starting of sleep diary completion (Day 0) and Month 6 (study termination) | |
Secondary | Sleep efficiency (SE) obtained by sleep diary | Ratio of total sleep time (TST) to time in bed (TIB) (multiplied by 100 to yield a percentage).
Subject records in his online sleep diary bedtime, wake-up time, time asleep, intra-night awakenings. |
Every night between starting of sleep diary completion (Day 0) and Month 6 (study termination) | |
Secondary | Sleep latency obtained by sleep diary | Length of time to accomplish the transition from full wakefulness to sleep. Subject records in his online sleep diary bedtime, wake-up time, time asleep, intra-night awakenings. | Every night between starting of sleep diary completion (Day 0) and Month 6 (study termination) | |
Secondary | Insomnia Severity Scale (ISI) score | 7-item questionnaire that assesses insomnia nature, severity and impact. | On Day 0, Week 5, Week 7, Month 4, Month 6 | |
Secondary | EQ-5-D | Standardized instrument for measuring generic health status. | On Day 0, Week 5, Week 7, Week 10, Month 4, Month 6 | |
Secondary | The Presleep State Arousal Scale (PSAS) | 16-item questionnaire assessing whether the respondent experienced somatic (8 items, eg heart rate) or cognitive hyperarousal (eg racing thoughts) at bedtime | On Day 0, Week 5, Week 7, Week 10, Month 4, Month 6 | |
Secondary | Hospital Anxiety and Depression Scale (HAD) | 14-item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. | On Day 0, Week 5, Week 7, Week 10, Month 4, Month 6 | |
Secondary | Short Version of the Functional Outcomes of Sleep Questionnaire (FOSQ) | 10 item questionnaire assessing the impact of excessive sleepiness on activities of daily living | On Day 0, Week 5, Week 7, Week 10, Month 4, Month 6 | |
Secondary | Rate of discontinuation and rate of reduction of anxiolytic hypnotic drugs and hypnotics | Every day anxiolytic hypnotic drugs and hypnotics daily dose | On Day 0, Week 5, Week 7, Week 10, Month 4, Month 6 | |
Secondary | Acceptability E-scale (AES) | 6-item self-reported questionnaire that evaluates the extent to which patients find E-health systems acceptable | On week 10 (after computerized behavioral therapy program) | |
Secondary | Client Satisfaction Questionnaire (CSQ-8) | 8-item questionnaire easily scored and administered measurement that is designed to measure client satisfaction with services. | On week 10 (after computerized behavioral therapy program) | |
Secondary | Sleep Condition Indicator (SCI) | brief 8-item scale which measures sleep problems against the DSM-5 criteria for insomnia disorder | On Day 0 | |
Secondary | The Pittsburgh Sleep Quality Index (PSQI) | self-report questionnaire that assesses sleep quality over a 1-month time interval | On Day 0 | |
Secondary | Cognitive Scale of Attachment to Benzodiazepines ("Echelle cognitive d'attachement aux benzodiazépines" ECAB) | 10-item scale assessing cognitive component of attachment to benzodiazepines | On Day 0 | |
Secondary | The Munich ChronoType Questionnaire (MCTQ) | Questionnaire to determine Chrono Type. | On Day 0 | |
Secondary | The Epworth Sleepiness Scale (ESS) | 8-item questionnaire assessing daytime sleepiness | On Day 0 | |
Secondary | Freiburg Mindfulness Inventory - short version (FMI) | questionnaire for measuring mindfulness | On Day 0 | |
Secondary | Krueger's personality inventory for DSM-5 in its brief form (PID-5-BF) | 25-item self-report questionnaire assessing the presence and severity of the five maladaptive personality traits outlined in DSM-5. | On Day 0 | |
Secondary | The Arousal Predisposition Scale (APS) | 12-item questionnaire assessing whether the respondent considers her/himself a stressful and emotionally reactive person | On Day 0 | |
Secondary | The Ford Insomnia to Stress Scale (FIRST) | 9-item questionnaire assessing whether past and future stressful events are likely to affect sleep quality | On Day 0 | |
Secondary | The "locus of control for technology"-questionnaire ("Kontrollüberzeugungen im Umgang mit Technik" - KUT) | 8-item questionnaire assessing the specific interaction with technical environments of users | On Day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT05963542 -
Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia
|
N/A | |
Completed |
NCT06339853 -
Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia
|
N/A | |
Recruiting |
NCT04069247 -
Effectiveness of eCBT-I on Improving Mental Health in Chinese Youths With Insomnia
|
N/A | |
Completed |
NCT04493593 -
Internet-delivered CBT-I (Space for Sleep): Pilot and Feasibility
|
N/A | |
Recruiting |
NCT06278077 -
Neurexan - a Clinical Trial in Short-Term Insomnia Patients
|
Phase 2 | |
Recruiting |
NCT05956886 -
Sleep Chatbot Intervention for Emerging Black/African American Adults
|
N/A | |
Completed |
NCT04661306 -
The Better Sleep for Supporters With Insomnia Study
|
N/A | |
Recruiting |
NCT06207279 -
Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale
|
||
Recruiting |
NCT06006299 -
Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC)
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Completed |
NCT04564807 -
Testing an Online Insomnia Intervention
|
N/A | |
Completed |
NCT03673397 -
The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression
|
N/A | |
Completed |
NCT04035200 -
Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation
|
Phase 2 | |
Active, not recruiting |
NCT05027438 -
Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention
|
N/A | |
Recruiting |
NCT06053840 -
An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients With Severe Insomnia
|
Phase 4 | |
Not yet recruiting |
NCT06348082 -
Project Women's Insomnia Sleep Health Equity Study (WISHES)
|
N/A | |
Not yet recruiting |
NCT06363799 -
Osteopathic Protocol for Insomnia in College Students
|
N/A | |
Not yet recruiting |
NCT05991492 -
Improving Sleep With a Digital Cognitive Behavioral Therapy for Insomnia Application
|
N/A | |
Not yet recruiting |
NCT06025968 -
Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis
|
N/A |